Trials / Terminated
TerminatedNCT01689506
Fluid Resuscitation in Patients Suffering From Burns Injury
Prospective Randomised Controlled Open-label Explorative Multi-centre Pilot Trial of Volulyte®-Supplemented Versus Albumin-supplemented Fluid Resuscitation for Major Burns
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Fresenius Kabi · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study compares two fluid resuscitation treatments in patients suffering from burns injury. The treatments are Volulyte® and Human Serum Albumin (HSA) which will be administered as infusion solutions. It will be evaluated whether Volulyte® is effective and safe, and provides any benefit.
Detailed description
Severe burns injury presents a unique resuscitation problem due to simultaneous loss of electrolyte and protein-rich exudate from the burn wound itself and leakage of fluid and protein from the circulation into the interstitial compartment. In the post shock phase of burn resuscitation, patients frequently suffer oedema of unburned tissues and organs and a positive fluid balance of many litres. This pilot study will compare two burns fluid resuscitation regimes (supplementation with 6% HES 130/0.4 in an isotonic electrolyte solution, Volulyte 6%, versus supplementation with Human Serum Albumin, HSA 50g/L) on patient outcome with particular regard to fluid balance at 24 hours after burns injury (primary variable).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volulyte | 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day. |
| DRUG | Human Serum Albumin | 5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit. |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2012-09-21
- Last updated
- 2014-06-26
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01689506. Inclusion in this directory is not an endorsement.